Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.

J Virol. 2008 Jul;82(13):6678-88. doi: 10.1128/JVI.00352-08. Epub 2008 Apr 23.

3.

Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.

He Y.

Curr Pharm Des. 2013;19(10):1800-9. Review.

PMID:
23092277
4.

Resistance to enfuvirtide, the first HIV fusion inhibitor.

Greenberg ML, Cammack N.

J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1. Review.

PMID:
15231762
5.

HIV entry inhibitors: mechanisms of action and resistance pathways.

Briz V, Poveda E, Soriano V.

J Antimicrob Chemother. 2006 Apr;57(4):619-27. Epub 2006 Feb 7. Review.

PMID:
16464888
6.

Inhibition of HIV-1 by fusion inhibitors.

Eggink D, Berkhout B, Sanders RW.

Curr Pharm Des. 2010;16(33):3716-28. Review.

PMID:
21128887
7.

Is there a future for antiviral fusion inhibitors?

Berkhout B, Eggink D, Sanders RW.

Curr Opin Virol. 2012 Feb;2(1):50-9. doi: 10.1016/j.coviro.2012.01.002. Epub 2012 Jan 28. Review.

PMID:
22440966
9.

Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.

Yu F, Lu L, Du L, Zhu X, Debnath AK, Jiang S.

Viruses. 2013 Jan 11;5(1):127-49. doi: 10.3390/v5010127. Review.

10.

Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.

Ashkenazi A, Wexler-Cohen Y, Shai Y.

Biochim Biophys Acta. 2011 Oct;1808(10):2352-8. doi: 10.1016/j.bbamem.2011.06.020. Epub 2011 Jul 5. Review.

Supplemental Content

Support Center